Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, shows significant benefit among patients with EGFR T790M mutation at disease progression. We analyzed the whole exome sequence of 48 samples obtained from 16 lung cancer patients with a longitudinal follow-up: treatment-naïve-baseline p...

詳細記述

書誌詳細

出版年:	Translational Oncology
主要な著者:	Asim Joshi, Ashwin Butle, Supriya Hait, Rohit Mishra, Vaishakhi Trivedi, Rahul Thorat, Anuradha Choughule, Vanita Noronha, Kumar Prabhash, Amit Dutt
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2022-08-01
主題:	Erlotinib resistance Low allele fraction EGFR T790M Osimertinib Orthotopic lung cancer mice model Bioluminescence imaging Next generation sequencing
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S1936523322001206